Mikael MD - Pfizer Chief Development
| PFE Stock | USD 26.74 0.09 0.34% |
Executive
Mikael MD is Chief Development of Pfizer Inc
| Age | 66 |
| Address | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has Return on Asset of 0.0331 % which means that on every $100 spent on assets, it made $0.0331 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0885 %, implying that it generated $0.0885 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of February 27, 2025, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 78.4 B, whereas Non Currrent Assets Other are projected to grow to (9.5 B).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Line Decker | Haleon plc | 51 | |
| Milano Furuta | Takeda Pharmaceutical Co | 47 | |
| Matthew Shields | Teva Pharma Industries | 51 | |
| JeanJacques Charhon | Bausch Health Companies | 60 | |
| MP MBA | Amphastar P | N/A | |
| Simon MD | Emergent Biosolutions | N/A | |
| William Hartzel | Emergent Biosolutions | N/A | |
| Tanya Zharov | Alvotech | 58 | |
| Jenny Steingrimsdottir | Alvotech | N/A | |
| Willie MD | Intracellular Th | N/A | |
| Michelle Pepin | Emergent Biosolutions | N/A | |
| Jessica Perl | Emergent Biosolutions | N/A | |
| Sandra Casaca | Alvotech | N/A | |
| Kelly Warfield | Emergent Biosolutions | N/A | |
| Molly Dir | Assertio Therapeutics | N/A | |
| Mary Pietryga | Assertio Therapeutics | N/A | |
| Mwana Lugogo | Takeda Pharmaceutical Co | 54 | |
| Aimee Lenar | Bausch Health Companies | N/A | |
| Bjorn Timelin | Haleon plc | N/A | |
| Karen Esq | Intracellular Th | 62 | |
| Eric Benevich | Neurocrine Biosciences | 60 | |
Management Performance
| Return On Equity | 0.0885 | ||||
| Return On Asset | 0.0331 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
| Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
| Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Lead Independent Director | ||
| James Smith, Independent Director | ||
| Christopher CFA, VP Officer | ||
| Nick Lagunowich, Global Medicine | ||
| Michael Mcdermott, Executive Vice President Chief Global Supply Officer | ||
| Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
| Susan DesmondHellmann, Independent Director | ||
| Francesca DeMartino, Chief Officer | ||
| Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
| Gordon Loh, Senior Vice President Corporate Audit | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| David Denton, Chief VP | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| Aamir Malik, Executive Vice President Chief Business Innovation Officer | ||
| Christopher Stevo, Senior Vice President and Chief Investor Relations Officer | ||
| DVM DVM, Chairman CEO | ||
| William Gray, Independent Director | ||
| Margaret Madden, Corporate VP | ||
| Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
| Susan Hockfield, Independent Director | ||
| William Carapezzi, Executive Vice President - Global Business Services and Transformation | ||
| Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
| Mikael MD, Chief Development | ||
| Albert DVM, Chairman CEO | ||
| Dan Littman, Independent Director | ||
| Payal Becher, Chief VP | ||
| FMedSci MD, Chief Development | ||
| James Kilts, Independent Director | ||
| James Quincey, Independent Director | ||
| Andreas Panayiotou, Global Officer | ||
| Susan Silbermann, Global Vaccines | ||
| Joseph Echevarria, Independent Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Payal Sahni, Executive Vice President, Chief People Experience Officer | ||
| Paivi Kerkola, Chief Italy | ||
| Angela Hwang, Group President - Pfizer Biopharmaceuticals Group | ||
| Mike Mcdermott, Executive Vice President Chief Global Supply Officer | ||
| Scott Gottlieb, Independent Director | ||
| Ronald Blaylock, Independent Director | ||
| Annette Doherty, Head Sciences |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0885 | ||||
| Return On Asset | 0.0331 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 206.39 B | ||||
| Shares Outstanding | 5.67 B | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 67.40 % | ||||
| Number Of Shares Shorted | 73.57 M | ||||
| Price To Earning | 9.48 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Dividend Share 1.68 | Earnings Share 1.39 | Revenue Per Share | Quarterly Revenue Growth 0.247 |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.